Skip to main content

Featured

Susie Wiles’ Revelations Expose Tensions in Trump’s Inner Circle

                                               Susie Wiles is the first woman to serve as White House chief of staff White House Chief of Staff Susie Wiles has offered a rare, candid glimpse into the internal strains of President Donald Trump’s administration , speaking openly in a series of interviews with author Chris Whipple. Wiles, the first woman to serve as Trump’s chief of staff, described the challenges of managing strong personalities and the often turbulent dynamics within the West Wing. Across more than ten interviews, Wiles painted a picture of an administration marked by conflict over immigration enforcement, government downsizing, and the president’s governing style . She characterized Trump as having “an alcoholic’s personality,” despite being a lifelong teetotaler, explaining that he operates with a sense of boundless confidence and...
Post a Comment
Read more

article

Labels

Alzheimer’s vaccines get a boost from new drug approval

 

After decades of disappointment and controversy, the field of Alzheimer’s disease research has finally seen a breakthrough with the approval of the first drug that targets the underlying pathology of the condition. 

Aducanumab, a monoclonal antibody that clears amyloid plaques from the brain, was granted accelerated approval by the US Food and Drug Administration in June 2021, despite mixed results from clinical trials and objections from some experts. 

The drug’s approval has rekindled interest in other therapeutic approaches that aim to prevent or slow down the progression of Alzheimer’s, such as vaccines that stimulate the immune system to attack amyloid or tau, another protein that accumulates in the brains of people with the disease. 

Several vaccine candidates are currently in various stages of development and testing, and some researchers are optimistic that they could offer a more effective and convenient way to treat Alzheimer’s than infusions of antibodies.


Labels:

Comments

Post a Comment